The gut-derived peptide glucagon-like peptide 2 has been suggested as a potential drug candidate for the treatment of various intestinal diseases.
However, the acute effects of glucagon-like peptide 2 on gastric functions as well as on glucose and lipid homeostasis in humans are less well characterized.
Dr Juris Meier and colleagues assessed pentagastrin-stimulated gastric acid output.
The team studied 15 healthy male volunteers with the intravenous infusion of glucagon-like peptide 2 or placebo over 120 minutes in the fasting state.
Another 15 healthy male volunteers were studied with 390 minutes infusion of glucagon-like peptide 2 or placebo during the ingestion of a solid test meal.
The research team determined gastric emptying using a 13C-sodium-octanote breath test.
|There was a 15% reduction in gastric acid and chloride secretion|
Plasma concentrations of glucose, insulin, C-peptide, glucagon, glucagon-like peptide 2, free fatty acids, free glycerol, and triglycerides were determined.
The researchers found that glucagon-like peptide 2 administration led to a marked increase in glucagon concentrations.
This increase in glucagons was noted both in the fasting state and during the meal study.
Postprandial plasma concentrations of triglycerides and free fatty acids were higher during glucagon-like peptide 2 infusion compared with placebo.
The team observed that glycerol concentrations were similar.
Glucagon-like peptide 2 administration caused a 15% reduction in pentagastrin-stimulated gastric acid and chloride secretion.
However, the team found that gastric emptying was not affected.
Dr Meier's team concluded, “Glucagon-like peptide 2 reduces gastric acid secretion but does not seem to have an influence on gastric emptying.”
“The stimulation of glucagon secretion by glucagon-like peptide 2 may counteract the glucagonostatic effect of glucagon-like peptide -1.”
“Changes in postprandial lipid excursions seem to reflect enhanced intestinal nutrient absorption during glucagon-like peptide 2 administration.”